Allergic rhinitis is a common condition caused by inflammation of nasal mucosa. The study was performed to gain information on this inflammation, including effect of intranasal corticosteroid treatment hereupon and potential influence on the lower airways, ie asthma.

The study was randomised, placebo-controlled double-blind in patients, monoallergic to grasspollen, presenting symptoms of rhinitis and asthma during season.

Treatment,ie intranasal corticosteroid or placebo, were given four weeks. After two weeks of treatment intranasal allergen challenge was performed. Measurements were performed during the full study period.

symptoms of allergic rhinitis for at least the two most recent grasspollen seasons

asthma symptoms of asthma for at least two of the four most recent grasspollen seasons

age 18 or older

Exclusion Criteria:

pregnancy or lactation

fertile women, not sterilised or using sufficient anticonception

Corticosteroid treatment (parenteral, oral, inhaled or intranasal) within two months prior to enrolment

Any other disease, condition or treatment, which to the discretion of the investigator has the potential to interfere with study results

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01657097